Compare OC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OC | ABVX |
|---|---|---|
| Founded | 1938 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.0B |
| IPO Year | N/A | N/A |
| Metric | OC | ABVX |
|---|---|---|
| Price | $122.10 | $116.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $148.08 | $118.33 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 02-23-2026 | 08-11-2025 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,659,000,000.00 | $6,231,374.00 |
| Revenue This Year | N/A | $6.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.69 | N/A |
| 52 Week Low | $97.53 | $4.77 |
| 52 Week High | $192.96 | $148.83 |
| Indicator | OC | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 64.84 | 44.18 |
| Support Level | $110.00 | $108.95 |
| Resistance Level | $117.80 | $129.56 |
| Average True Range (ATR) | 3.30 | 7.90 |
| MACD | 0.66 | -2.73 |
| Stochastic Oscillator | 96.83 | 18.66 |
Owens-Corning Inc is a manufacturer of glass fiber utilized in composites and building materials. It has an integrated business model with four reportable segments: Composites, Insulation, Doors, and Roofing. It generates maximum revenue from the Roofing segment. Its Roofing segment laminate and strip asphalt roofing shingles, roofing components, synthetic packaging materials, and oxidized asphalt. It meets the growing demand for longer-lasting, aesthetically attractive laminate products with modest capital investment. Geographically the company generates the majority of its revenue from the United States.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.